COVID-19 Omicron (B.1.1.529) Variant
This talking points document was developed by the iREACH Subject Matter Experts to provide information on the COVID-19 Omicron variant.
This talking points document was developed by the iREACH Subject Matter Experts to provide information on the COVID-19 Omicron variant.
This talking points document was developed by iREACH Subject Matter Experts to provide information on fertility, pregnancy and COVID-19 vaccines.
This talking points document was developed by iREACH Subject Matter Experts Dr. Yabo Beysolow and Lisa Jacques-Carroll to provide updated information on COVID-19 vaccine booster doses.
This talking points document was developed by iREACH Subject Matter Experts Dr. Yabo Beysolow and Lisa Jacques-Carroll to provide information on the few cases of myocarditis reported in individuals who received the Pfizer or Moderna COVID-19 vaccines.
On December 9, 2022, the CDC (following authorization by the FDA), CDC expanded the use of updated (bivalent) COVID-19 booster vaccines for children ages 6 months through 5 years. Learn more here.
This talking points document was developed by iREACH Subject Matter Experts to provide information on the few cases of GBS reported in individuals who received the J & J COVID-19 vaccines.
This talking points document, available in Spanish and English, was developed by iREACH Subject Matter Experts Dr. Yabo Beysolow and Lisa Jacques-Carroll to provide detailed information on the first approved oral antiviral pill for COVID-19 disease.
The wave three report of Understanding Diverse Communities and Supporting Equitable and Informed Vaccination Decision-Making been released.
This infographic provides actionable recommendations for stakeholders to decrease vaccine hesitancy.
Learn how you can support decision-making in individuals and consider if, and when a COVID-19 vaccination might be right with this infographic.